George W. Sledge on Muck Rack

George W. Sledge

Palo Alto
As seen in: Nature, JAMA Oncology, JAMA: Journal of the American Medical Association, Oncology Times, Cell Press, HemOnc Today, OncLive, Press Release Point, Health Management, Targeted Oncology
Professor of Medicine, Stanford University; breast cancer doc
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with George W.

Contact George W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer - npj Precision Oncology

|
By Ibrahim Halil Sahin, Ibrahim Şahin, Joanne Xiu, Yasmine Baca, Moh’d Khushman, Axel Grothey, Shafia Rahman, Benjamin A. Weinberg, Sanjay Goel, Mehmet Akce, Vikram C. Gorantla, Emil Lou, Anup Kasi, Anthony Shields, George W. Sledge, John Paul Shen, Anwaar Saeed, Emily Palumbo, Matt Oberley, Mohammedtaki Tejani
| Nature
Abstract Class II and III BRAF mutations are uncommon events, with limited data on their clinical and biological characteristics. We investigated clinical and molecular features of BRAF mutation classes in a total of 24,402 patients with mismatch repair proficient CRC (MMRp). Samples collected between 2006 and 2023 were profiled using next-generation sequencing and whole-transcriptome sequencing.
Open in Who Shared Issue with article?
|
By Matthew J Oberley, George W. Sledge
| Press Release Point
Groundbreaking study in Communications Medicine highlights AI’s role in transforming immunotherapy decisions and precision oncology IRVING, Texas, August 6, 2025 – Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a new study in Communications Medicine , a Nature portfolio journal, demonstrating that Caris’ AI-based image analysis model has the potential to more accurately predict cancer biomarkers...
Open in Who Shared View Duplicates (139) Issue with article?

Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis

|
By David Spetzler, George W. Sledge
| Press Release Point
Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas, July 22, 2025 – Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and further reinforcing its leadership in precision oncology.
Open in Who Shared View Duplicates (28) Issue with article?
See all 35 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with George W.

Contact George W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified